고령자 빈혈 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9.3%로 43억 2,000만 달러로 성장할 전망입니다. 예측 기간 중 예상되는 성장의 원동력은 고령화, 만성질환의 유병률 증가, 진단 툴의 발전, 의료에 대한 인식 개선, 치료 접근성 향상 등입니다. 이 기간의 주요 동향으로는 AI 기반 진단, 웨어러블 건강 모니터, 첨단 혈액 분석 툴, 원격의료 통합, 맞춤형 의료 솔루션 등이 있습니다.
노인 인구 증가는 노인 빈혈 시장의 성장을 촉진할 것으로 예측됩니다. 평균 수명 연장, 출산율 감소, 대규모 코호트 고령화 등 세계 인구의 고령화에 따라 65세 이상 노인의 비율이 꾸준히 증가하고 있습니다. 이러한 인구 통계학적 변화는 노인의 빈혈의 중요한 원인인 노화 관련 질환과 만성질환의 유병률 증가로 이어집니다. 영양 부족, 만성질환, 노화 등의 요인으로 인한 노인 빈혈 사례 증가는 이 질환의 진단, 관리 및 치료에 대한 수요를 촉진하고 있습니다. 예를 들어 2024년 7월 영국 통계청(ONS)은 영국의 65세 이상 인구가 2021년 1,100만 명에서 2022년 1,270만 명으로 증가했다고 보고했습니다. 이러한 노인 인구 증가는 노인 빈혈 시장의 확대를 주도하고 있습니다.
고령자 빈혈 시장의 주요 기업은 치료 과정을 최적화하고, 환자의 치료 효과를 높이고, 부작용을 최소화하고, 전체 의료 서비스의 효율성을 향상시키기 위해 기술 혁신, 특히 개인 맞춤형 치료에 집중하고 있습니다. 맞춤형 치료는 각 환자의 고유한 요구에 맞춘 치료법입니다. 예를 들어 인도에 본사를 둔 카디라 파마슈티컬스(Kadira Pharmaceuticals)는 2024년 3월 경구용 철분제를 복용할 수 없는 환자의 철분 결핍성 빈혈 치료를 위한 새로운 철분 주사제인 레드샷 FCM(Redshot FCM)을 출시했습니다. Redshot FCM은 철분 전달과 흡수를 향상시키기 위해 고급 카르복시 말토오스 철을 사용하여 충분한 철분을 공급하고 높은 안전 기준을 유지합니다. 이번 개발은 환자 개개인의 필요에 맞는 치료법을 개발하여 의료를 발전시키고 궁극적으로 철 결핍성 빈혈 환자의 결과를 개선하기 위한 우리의 노력을 강조하는 것입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 고령자 빈혈 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 고령자 빈혈 시장 : 성장률 분석
- 세계의 고령자 빈혈 시장 실적 : 규모와 성장, 2019-2024
- 세계의 고령자 빈혈 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 고령자 빈혈 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 고령자 빈혈 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 태블릿
- 주사제
- 세계의 고령자 빈혈 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 철 보충제
- 에리스로포이에틴 또는 적혈구 자극제
- 비타민 B12 보충제
- 엽산 보충제
- 세계의 고령자 빈혈 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 비경구
- 세계의 고령자 빈혈 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 온라인 약국
- 소매 약국
- 세계의 고령자 빈혈 시장, 정제의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 철 보충제
- 비타민 B12 보충제
- 엽산정
- ESA(Erythropoiesis-Stimulating Agents) 정제
- 세계의 고령자 빈혈 시장, 주사제의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 철제 주사
- 비타민 B12 주사
- ESA(Erythropoiesis-Stimulating Agents) 주사
- 엽산 주사
제7장 지역별·국가별 분석
- 세계의 고령자 빈혈 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 고령자 빈혈 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 고령자 빈혈 시장 : 경쟁 구도
- 고령자 빈혈 시장 : 기업 개요
- Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
- Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Novartis International AG
- Takeda Pharmaceutical Company Limited
- Amgen Inc
- Japan Tobacco Inc
- Fresenius Medical Care AG
- Teva Pharmaceutical Industries Ltd
- Sandoz International GmbH
- CSL Limted
- Daiichi Sankyo Company Limited
- Amag Pharmaceuticals
- Akebia Therapeutics Inc
- Pharmacosmos A/S
- Rockwell Medical Inc
- Bioage Labs Inc
- Shield Therapeutics Plc
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 고령자 빈혈 시장 2029 : 새로운 기회를 제공하는 국가
- 고령자 빈혈 시장 2029 : 새로운 기회를 제공하는 부문
- 고령자 빈혈 시장 2029 : 성장 전략
제36장 부록
KSA
Anemia in the elderly refers to a condition where the number of red blood cells (RBCs) or hemoglobin levels falls below the normal range, reducing the blood's ability to carry oxygen in older adults (typically those aged 65 and older). This condition is often caused by nutritional deficiencies, chronic illnesses, or age-related physiological changes.
The main products used to treat anemia in the elderly include tablets and injectables. Tablets are solid oral medications commonly prescribed for older adults with anemia. Treatment options include iron supplements, erythropoietin or erythrocyte-stimulating agents, vitamin B12 supplements, and folic acid supplements. These treatments can be administered orally or parenterally and are typically provided through hospital pharmacies, online pharmacies, and retail pharmacies.
The anemia in elderly market research report is one of a series of new reports from The Business Research Company that provides anemia in elderly market statistics, including anemia in elderly industry global market size, regional shares, competitors with a anemia in elderly market share, detailed anemia in elderly market segments, market trends and opportunities, and any further data you may need to thrive in the anemia in elderly industry. This anemia in elderly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anemia in elderly market size has grown strongly in recent years. It will grow from $2.75 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historical period can be attributed to factors such as nutritional deficiencies, chronic diseases, inflammation, bone marrow disorders, and blood loss.
The anemia in elderly market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%.The anticipated growth in the forecast period is driven by an aging population, a rising prevalence of chronic diseases, advancements in diagnostic tools, increased healthcare awareness, and better access to treatment. Key trends during this period include AI-driven diagnostics, wearable health monitors, advanced blood analysis tools, telehealth integration, and personalized medicine solutions.
The growing elderly population is expected to drive the growth of the anemia in the elderly market. As the global population ages, with increased life expectancy, declining birth rates, and the aging of large cohorts, the proportion of individuals aged 65 and older is steadily increasing. This demographic shift leads to a higher prevalence of age-related and chronic conditions, which are significant causes of anemia in older adults. The rise in cases of anemia among the elderly, due to factors such as nutritional deficiencies, chronic diseases, and the effects of aging, is fueling the demand for diagnosis, management, and treatment of the condition. For example, in July 2024, the Office for National Statistics (ONS) reported that the number of people aged 65 and older in the UK grew to 12.7 million in 2022 from 11 million in 2021. This growth in the elderly population is driving the expansion of the anemia in the elderly market.
Leading companies in the elderly anemia market are concentrating on technological innovations, particularly personalized treatments, to optimize the treatment process, enhance patient results, minimize side effects, and improve overall healthcare efficiency. Personalized treatments are tailored to the unique needs of each patient. For example, in March 2024, Cadila Pharmaceuticals, based in India, unveiled Redshot FCM, a new iron injection aimed at treating iron deficiency anemia in patients who cannot tolerate oral iron. This intravenous formulation provides sufficient iron and maintains a high safety standard. Redshot FCM utilizes an advanced Ferric Carboxymaltose formula to enhance iron delivery and absorption. This development highlights a commitment to advancing healthcare by creating therapies tailored to individual patient needs, ultimately leading to improved outcomes for those with iron deficiency anemia.
In August 2022, CSL Limited, an Australian biotechnology company, acquired Vifor Pharma AG, a Swiss pharmaceutical company specializing in treatments for iron deficiency, especially among elderly patients and those with chronic kidney disease (CKD). This acquisition strengthens CSL's leadership in the iron deficiency anemia market and expands its presence in addressing the needs of various patient populations, further propelling the growth of treatments for anemia in the elderly.
Major players in the anemia in elderly market are Johnson & Johnson, Roche Holding AG, Merck & Co Inc, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Japan Tobacco Inc, Fresenius Medical Care AG, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, CSL Limted, Daiichi Sankyo Company Limited, Amag Pharmaceuticals, Akebia Therapeutics Inc, Pharmacosmos A/S, Rockwell Medical Inc, Bioage Labs Inc, Shield Therapeutics Plc, MegaPro Biomedical Co Ltd.
North America was the largest region in the anemia in elderly market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anemia in elderly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anemia in elderly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anemia in elderly market consists of revenues earned by entities by providing services such as diagnostic testing, medical consultations and treatment plans, and administration of iron infusions or blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The anemia in elderly market also includes sales of iron supplements, vitamin B12, folic acid supplements, and diagnostic equipment such as hemoglobin meters and blood test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Anemia In Elderly Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on anemia in elderly market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for anemia in elderly ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anemia in elderly market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product Type: Tablets, Injectable
- 2) By Treatment: Iron Supplements, Erythropoietin Or Erythrocyte-Stimulating Agents, Vitamin B12 Supplements, Folic Acid Supplements
- 3) By Route Of Administration: Oral, Parenteral
- 4) By End User: Hospital pharmacy, Online Pharmacy, Retail pharmacy
- Subsegments:
- 1) By Tablets: Iron Supplements; Vitamin B12 Supplements; Folic Acid Tablets; Erythropoiesis-Stimulating Agents (ESAs) Tablets
- 2) By Injectable: Iron Injections; Vitamin B12 Injections; Erythropoiesis-Stimulating Agents (ESAs) Injections; Folic Acid Injections
- Companies Mentioned: Johnson & Johnson; Roche Holding AG; Merck & Co Inc; Bristol-Myers Squibb Company; AstraZeneca plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Anemia In Elderly Market Characteristics
3. Anemia In Elderly Market Trends And Strategies
4. Anemia In Elderly Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Anemia In Elderly Growth Analysis And Strategic Analysis Framework
- 5.1. Global Anemia In Elderly PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Anemia In Elderly Market Growth Rate Analysis
- 5.4. Global Anemia In Elderly Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Anemia In Elderly Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Anemia In Elderly Total Addressable Market (TAM)
6. Anemia In Elderly Market Segmentation
- 6.1. Global Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tablets
- Injectable
- 6.2. Global Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Iron Supplements
- Erythropoietin Or Erythrocyte-Stimulating Agents
- Vitamin B12 Supplements
- Folic Acid Supplements
- 6.3. Global Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- 6.4. Global Anemia In Elderly Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital pharmacy
- Online Pharmacy
- Retail pharmacy
- 6.5. Global Anemia In Elderly Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Iron Supplements
- Vitamin B12 Supplements
- Folic Acid Tablets
- Erythropoiesis-Stimulating Agents (ESAs) Tablets
- 6.6. Global Anemia In Elderly Market, Sub-Segmentation Of Injectable, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Iron Injections
- Vitamin B12 Injections
- Erythropoiesis-Stimulating Agents (ESAs) Injections
- Folic Acid Injections
7. Anemia In Elderly Market Regional And Country Analysis
- 7.1. Global Anemia In Elderly Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Anemia In Elderly Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Anemia In Elderly Market
- 8.1. Asia-Pacific Anemia In Elderly Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Anemia In Elderly Market
- 9.1. China Anemia In Elderly Market Overview
- 9.2. China Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Anemia In Elderly Market
- 10.1. India Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Anemia In Elderly Market
- 11.1. Japan Anemia In Elderly Market Overview
- 11.2. Japan Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Anemia In Elderly Market
- 12.1. Australia Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Anemia In Elderly Market
- 13.1. Indonesia Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Anemia In Elderly Market
- 14.1. South Korea Anemia In Elderly Market Overview
- 14.2. South Korea Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Anemia In Elderly Market
- 15.1. Western Europe Anemia In Elderly Market Overview
- 15.2. Western Europe Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Anemia In Elderly Market
- 16.1. UK Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Anemia In Elderly Market
- 17.1. Germany Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Anemia In Elderly Market
- 18.1. France Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Anemia In Elderly Market
- 19.1. Italy Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Anemia In Elderly Market
- 20.1. Spain Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Anemia In Elderly Market
- 21.1. Eastern Europe Anemia In Elderly Market Overview
- 21.2. Eastern Europe Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Anemia In Elderly Market
- 22.1. Russia Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Anemia In Elderly Market
- 23.1. North America Anemia In Elderly Market Overview
- 23.2. North America Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Anemia In Elderly Market
- 24.1. USA Anemia In Elderly Market Overview
- 24.2. USA Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Anemia In Elderly Market
- 25.1. Canada Anemia In Elderly Market Overview
- 25.2. Canada Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Anemia In Elderly Market
- 26.1. South America Anemia In Elderly Market Overview
- 26.2. South America Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Anemia In Elderly Market
- 27.1. Brazil Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Anemia In Elderly Market
- 28.1. Middle East Anemia In Elderly Market Overview
- 28.2. Middle East Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Anemia In Elderly Market
- 29.1. Africa Anemia In Elderly Market Overview
- 29.2. Africa Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Anemia In Elderly Market Competitive Landscape And Company Profiles
- 30.1. Anemia In Elderly Market Competitive Landscape
- 30.2. Anemia In Elderly Market Company Profiles
- 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
31. Anemia In Elderly Market Other Major And Innovative Companies
- 31.1. Novartis International AG
- 31.2. Takeda Pharmaceutical Company Limited
- 31.3. Amgen Inc
- 31.4. Japan Tobacco Inc
- 31.5. Fresenius Medical Care AG
- 31.6. Teva Pharmaceutical Industries Ltd
- 31.7. Sandoz International GmbH
- 31.8. CSL Limted
- 31.9. Daiichi Sankyo Company Limited
- 31.10. Amag Pharmaceuticals
- 31.11. Akebia Therapeutics Inc
- 31.12. Pharmacosmos A/S
- 31.13. Rockwell Medical Inc
- 31.14. Bioage Labs Inc
- 31.15. Shield Therapeutics Plc
32. Global Anemia In Elderly Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Anemia In Elderly Market
34. Recent Developments In The Anemia In Elderly Market
35. Anemia In Elderly Market High Potential Countries, Segments and Strategies
- 35.1 Anemia In Elderly Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Anemia In Elderly Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Anemia In Elderly Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
